EP Patent

EP3262039A4 — Process for the preparation of amorphous (1s)-1,5-anhvdro-1-[3-[[5-(4 fluorophennyl)-2-thienyl]methvl]-4-methylphenyl]-d-glucitol and its polymorphs thereof

Assigned to MSN Laboratories Pvt Ltd · Expires 2018-11-14 · 8y expired

What this patent protects

Patent listed against Invokana.

Drugs covered by this patent

Patent Metadata

Patent number
EP3262039A4
Jurisdiction
EP
Classification
—
Expires
2018-11-14
Drug substance claim
No
Drug product claim
No
Assignee
MSN Laboratories Pvt Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.